The
immunomodulatory family of Siglecs recognizes sialic acid-containing
glycans as “self”, which is exploited
in cancer for immune evasion. The biochemical nature of Siglec ligands
remains incompletely understood, with emerging evidence suggesting
the importance of carbohydrate sulfation. Here, we investigate how
specific sulfate modifications affect Siglec ligands by overexpressing
eight carbohydrate sulfotransferases (CHSTs) in five cell lines. Overexpression
of three CHSTsCHST1, CHST2, or CHST4significantly
enhance the binding of numerous Siglecs. Unexpectedly, two other CHSTs
(Gal3ST2 and Gal3ST3) diminish Siglec binding, suggesting a new mode
to modulate Siglec ligands via sulfation. Results are cell type dependent,
indicating that the context in which sulfated glycans are presented
is important. Moreover, a pharmacological blockade of N- and O-glycan maturation reveals a cell-type-specific
pattern of importance for either class of glycan. Production of a
highly homogeneous Siglec-3 (CD33) fragment enabled a mass-spectrometry-based
binding assay to determine ≥8-fold and ≥2-fold enhanced
affinity for Neu5Acα2–3(6-O-sulfo)Galβ1–4GlcNAc
and Neu5Acα2–3Galβ1–4(6-O-sulfo)GlcNAc, respectively, over Neu5Acα2–3Galβ1–4GlcNAc.
CD33 shows significant additivity in affinity (≥28-fold) for
the disulfated ligand, Neu5Acα2–3(6-O-sulfo)Galβ1–4(6-O-sulfo)GlcNAc. Moreover,
joint overexpression of CHST1 with CHST2 in cells greatly enhanced
the binding of CD33 and several other Siglecs. Finally, we reveal
that CHST1 is upregulated in numerous cancers, correlating with poorer
survival rates and sodium chlorate sensitivity for the binding of
Siglecs to cancer cell lines. These results provide new insights into
carbohydrate sulfation as a general mechanism for tuning Siglec ligands
on cells, including in cancer.